Frazier Taps CDMO Architect Milton Boyer to Build Next Pharma Platform

SEATTLE, WA – June 02, 2026 – Frazier Healthcare Partners, a private equity firm with a three-decade focus on healthcare, announced it has brought veteran pharmaceutical executive Milton Boyer on board as an Executive in Residence (EIR). While personnel announcements are routine, this move is a calculated signal of intent, revealing a core component of the firm's strategy: embedding operational masters to navigate and dominate highly complex, regulated markets. Boyer's appointment is not just about adding a name to the letterhead; it's about acquiring a blueprint for success in the critical, and often turbulent, world of pharmaceutical manufacturing.

In a world still grappling with the lessons of supply chain fragility, the role of Contract Development and Manufacturing Organizations (CDMOs) has shifted from a back-office function to a strategic imperative. Frazier's decision to bring in a leader of Boyer's caliber suggests the firm is preparing for a significant new investment platform in this space, leveraging its recently closed, and oversubscribed, $2.3 billion Growth Buyout Fund XI.

A Specialist for a Specialized Market

Milton Boyer’s nearly 30-year career is a case study in value creation within the pharmaceutical services sector. His track record is not one of steady, peacetime leadership but of transformative action in high-stakes environments. He is, in essence, a specialist in complexity.

Most recently, as CEO of Kindeva Drug Delivery, he was tasked with a monumental challenge: carving out 3M's drug delivery business and merging it with Meridian Medical Technologies. Such corporate carve-outs are notoriously difficult, fraught with operational entanglement and cultural friction. Boyer not only managed the integration but also executed strategic add-on acquisitions, successfully forging a new, standalone leader in the drug-device combination space. This experience—taking a non-core asset from a massive conglomerate and building it into a focused powerhouse—is precisely the kind of expertise that private equity covets.

Prior to Kindeva, his tenure as CEO of SCA Pharmaceuticals demonstrated a different but equally valuable skill: building from the ground up. He oversaw the development of a new greenfield manufacturing facility and scaled the 503B sterile compounding company into one of the nation's foremost suppliers of ready-to-use sterile drugs for hospitals. This involved not just construction and logistics, but navigating the intense regulatory scrutiny that governs sterile manufacturing, a field where a single misstep can have catastrophic consequences for patients and the business.

His career is bookended by similar feats, including leading Oso BioPharmaceuticals Manufacturing, a sterile injectable CDMO carved out from Catalent, which was later successfully sold to AMRI. This pattern of acquiring, building, and exiting complex manufacturing assets demonstrates a rare and repeatable skill set. Combined with his background as a U.S. Army Captain and his academic training in biochemistry, Boyer embodies the blend of disciplined leadership and deep technical knowledge required in this sector.

The "EIR-Centric" Playbook

Boyer's role as an Executive in Residence is central to understanding Frazier's methodology. Unlike some firms where EIRs serve as passive advisors, Frazier's model is explicitly "EIR-centric." These executives are not waiting for deals to cross their desk; they are the architects of the investment thesis. They are tasked with identifying market trends and unmet needs, sourcing potential platform acquisitions, and leading the due diligence process with an operator's eye for what truly works—and what could go wrong.

"Milton has built an exceptional track record leading complex businesses in highly regulated markets serving the life sciences industry," noted Jeremy Janson, a Principal at Frazier. "His combination of hands-on operating experience, deep relationships, and industry thought leadership makes him an ideal partner as we look to identify and build a market-leading platform."

Once an acquisition is made, the EIR often steps in as CEO or Chairman of the new portfolio company, ensuring the strategic vision developed during sourcing is executed flawlessly. This integration of deal-making and operations is designed to mitigate risk and accelerate growth. By embedding an expert like Boyer, Frazier effectively internalizes decades of hard-won experience, allowing the firm to underwrite deals that other investors, lacking such deep domain expertise, might deem too risky.

Targeting the Pharmaceutical Supply Chain

Frazier's interest in the pharmaceutical supply chain is well-established. The firm's portfolio already includes Packaging Coordinators Inc. (PCI), a major player providing drug development, manufacturing, and packaging services. It also holds a stake in CSafe Global, a key provider of cold chain shipping solutions vital for biologics and vaccines. These investments reveal a strategic focus on the essential infrastructure that underpins the entire biopharmaceutical industry.

The hiring of Boyer is the next logical step in this thesis. It signals a move to go deeper, likely targeting a platform in the sterile manufacturing or complex formulation space where Boyer's expertise is most potent. The CDMO market is ripe for such a strategy. It remains a fragmented industry with many founder-owned or corporately-orphaned assets that are prime candidates for the kind of operational transformation Boyer has repeatedly engineered.

Furthermore, the macro trends are favorable. The push for on-shoring and securing domestic supply chains, the rise of advanced therapeutics like cell and gene therapies that require specialized manufacturing capabilities, and the continued outsourcing by large pharma to streamline their own operations all create powerful tailwinds for the CDMO sector. Boyer's appointment positions Frazier to not just ride these waves, but to build the ships that will navigate them.